immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision’s BioSimTM anti-Bevacizumab ELISA kit is designed to quantify/measure the antibody against Bevacizumab with high specificity and sensitivity in biological matrices.
产品特点
Easy, convenient, sensitive and time-saving method to measure the level of antibody against Bevacizumab in human serum and plasma.
Detection Range: 62 - 500 ng/ml
Sensitivity: 30 ng/ml
Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100)
Cross Reactivity: Bevacizumab infusion camouflages/masks the presence of antibody to Bevacizumab (ATA) in serum/plasma samples. Therefore, blood sampling time is critical for detection of ATA. It is convenient to obtain blood sample just before the infusion of Bevacizumab or at least 2 weeks after the infusion of Bevacizumab.
Recovery rate: 85 – 115% with normal human serum samples with known concentrations